SMG9

Across TCGA pan-cancer cohorts, SMG9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMG9 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SMG9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMG9 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LSCC are the cancer types where SMG9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	24	view →
CCRCC	DFS	Tertile	IV	0.162	0.908	.024	7	view →
LSCC	OS	Median	III,IV	0.664	0.996	.015	5	view →
HNSC	OS	Quartile	III,IV	0.270	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMG9–PDAC (DFS)

Open the PDAC breakdown →